The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia

International Journal of Geriatric Psychiatry

Volumn 25, Issue 10, 2010, Pages 1030-1038

  Larsson, Victoria ^a   Aarsland, Dag ^b,d   Ballard, Clive ^c   Minthon, Lennart ^a   Londos, Elisabet ^a  

^a LUND UNIVERSITY   (Sweden)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

dementia with Lewy bodies; Parkinson's disease dementia; REM sleep behaviour disorder; sleep disorder

Indexed keywords

MEMANTINE; PLACEBO;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHYSICAL ACTIVITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP DISORDER; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; DOPAMINE AGENTS; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MEMANTINE; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; QUESTIONNAIRES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 78649409851     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2506     Document Type: Article

References (42)

1. Aarsland D, Ballard C, Walker Z, et al., 2009. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8: 613-618.
2. Adler CH, Thorpy MJ,. 2005. Sleep issues in Parkinson's disease. Neurology 64: S12-20.
3. Arnulf I, Leu S, Oudiette D,. 2008. Abnormal sleep and sleepiness in Parkinson's disease. Curr Opin Neurol 21: 472-477.
4. Boddy F, Rowan EN, Lett D, et al., 2007. Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 22: 529-535.
5. Boeve BF, Dickson DW, Olson EJ, et al., 2007a. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 8: 60-64.
6. Boeve BF, Silber MH, Ferman TJ,. 2003a. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 4: 281-284.
7. Boeve BF, Silber MH, Ferman TJ,. 2004. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatr Neurol 17: 146-157.
8. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE,. 2001. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16: 622-630.
9. Boeve BF, Silber MH, Parisi JE, et al., 2003b. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 61: 40-45.
10. Boeve BF, Silber MH, Saper CB, et al., 2007b. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130: 2770-2788.
11. Cantor CR, Stern MB,. 2002. Dopamine agonists and sleep in Parkinson's disease. Neurology 58: S71-S78.
12. Carley DW, Olopade C, Ruigt GS, Radulovacki M,. 2007. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 30: 35-41.
13. Chiu HF, Wing YK, Lam LC, et al., 2000. Sleep-related injury in the elderly-an epidemiological study in Hong Kong. Sleep 23: 513-517.
14. De Cock VC, Vidailhet M, Arnulf I,. 2008. Sleep disturbances in patients with parkinsonism. Nat Clin Pract Neurol 4: 254-266.
15. Emre M,. 2009. Memantine: a new hope for treatment of Lewy body-related dementias? Lancet Neurol 8: 594-595.
16. Emre M, Aarsland D, Albanese A, et al., 2004. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509-2518.
17. Gjerstad MD, Aarsland D, Larsen JP,. 2002. Development of daytime somnolence over time in Parkinson's disease. Neurology 58: 1544-1546.
18. Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP,. 2008. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time. J Neurol Neurosurg Psychiatr 79: 387-391.
19. Grace JB, Walker MP, Mckeith IG,. 2000. A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatr 15: 1028-1033.
20. Ishida T, Kamei C,. 2009. Characteristic effects of anti-dementia drugs on rat sleep patterns. J Pharmacol Sci 109: 449-455.
21. Johns MW,. 1991. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14: 540-545.
22. Kunz D, Bes F,. 1997. Melatonin effects in a patient with severe REM sleep behavior disorder: case report and theoretical considerations. Neuropsychobiology 36: 211-214.
23. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A,. 2009. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 24: 1217-1221.
24. Lippa CF, Duda JE, Grossman M, et al., 2007. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68: 812-819.
25. Mahowald MW, Bundlie SR, Hurwitz TD, Schenck CH,. 1990. Sleep violence-forensic science implications: polygraphic and video documentation. J Forensic Sci 35: 413-432.
26. Mckeith I, Del Ser T, Spano P, et al., 2000. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036.
27. Mckeith IG, Dickson DW, Lowe J, et al., 2005. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872.
28. Medicine AAOS,. 2005. The international classification of sleep disorders, revised: Diagnostic and coding manual. Chicago, IL, American Academy of Sleep Medicine.
29. Ohayon MM, Caulet M, Priest RG,. 1997. Violent behavior during sleep. J Clin Psychiatr 58: 369-376; quiz 377.
30. Olson EJ, Boeve BF, Silber MH,. 2000. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 123 (Pt 2): 331-339.
31. Sara SJ,. 2009. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 10: 211-223.
32. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW,. 1986. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 9: 293-308.
33. Schenck CH, Garcia-Rill E, Skinner RD, Anderson ML, Mahowald MW,. 1996. A case of REM sleep behavior disorder with autopsy-confirmed Alzheimer's disease: postmortem brain stem histochemical analyses. Biol Psychiatr 40: 422-425.
34. Schenck CH, Mahowald MW,. 2002. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 25: 120-138.
35. Schredl M, Weber B, Braus D, et al., 2000. The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol 35: 243-249.
36. Sforza E, Krieger J, Petiau C,. 1997. REM sleep behavior disorder: clinical and physiopathological findings. Sleep Med Rev 1: 57-69.
37. Takeuchi N, Uchimura N, Hashizume Y, et al., 2001. Melatonin therapy for REM sleep behavior disorder. Psychiatr Clin Neurosci 55: 267-269.
38. Tandberg E, Larsen JP, Karlsen K,. 1998. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 13: 895-899. (Pubitemid 28517665)
39. Tandberg E, Larsen JP, Karlsen K,. 1999. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 14: 922-927.
40. Thomas SJ, Grossberg GT,. 2009. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 4: 367-377.
41. Tractenberg RE, Singer CM, Kaye JA,. 2005. Symptoms of sleep disturbance in persons with Alzheimer's disease and normal elderly. J Sleep Res 14: 177-185.
42. Wiegand MH,. 2008. Antidepressants for the treatment of insomnia: a suitable approach? Drugs 68: 2411-2417.